Publication Cabral P, ResearchSquare (2022) (preprint)
Dates: 2022-01-15 to 2022-05-30
Funding: Not reported/unclear (The authors thank HRH Pharmaceuticals Limited, Instituto Galzu, as well as all the professionals who, with their efforts made this research possible.)
Conflict of interest: No
Blinding: double blinding
Multicenter / Brazil |
Follow-up duration (days): 60
5 mg (five 1 mg tablets) orally once a day for up to 14 days
|Characteristics of participants|
Mean age : NR
Severity : Mild: n= 281/ Asymptomatic: n=0
Number of vaccinated participants: NR
|In the register|
1) Proportion of patients hospitalized during the study through day 28 [Time Frame: Day 14 to Day 30]: WHO clinical progression ordinal scale (Jun/2020), Score 4 to 10. Health Organization Ordinal Clinical Progression Scale (WHO, Jun/2020; scale 0 [asymptomatic] to 10 [death]), with score 4 to 7.
2) Proportion of participants with a clinical outcome of CURE during the study; [Time Frame: Day 14 to Day 30]: The clinical outcome of cure is defined in this protocol as the absence of viral RNA in samples collected and clinical conditions for outpatient discharge.
|In the report|
Proportion of patients hospitalized during the study through day 28, according to the WHO Ordinary Clinical Progression Scale (Jun/2020), Score 4 to 10.
Yes. In English
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
|General comment||In addition to the preprint and its supplement, the protocol and study registry were used in data extraction and risk of bias assessment. The study achieved the target sample size specified in the trial registry and protocol. There is no change from the trial registration in the intervention and control treatments. The registry has an additional primary outcome that is not reflected in the reported primary outcomes.|